DREAM Challenges

Anti-PD1 Response Prediction DREAM Challenge

Anti-PD1 Response Prediction

The Bristol Myers Squibb-Sage Bionetworks Anti–PD-1 Response Prediction DREAM Challenge is the first DREAM initiative and collaboration in the I-O space. While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy, there remains a need to improve the ability to predict which patients are more likely to receive benefit from treatment with I-O. The goal of this challenge is to leverage clinical and biomarker data to develop predictive models of response to I-O therapy in lung cancer and ultimately gain insights that may facilitate potential novel monotherapies or combinations with I-O. REGISTER NOW